GeNeuro starts Phase IIa of GNbAC1 in Type I diabetes

In April, GeNeuro S.A. (Euronext:GNRO) began a Phase IIa trial to evaluate GNbAC1 in about 60 recently diagnosed adults with Type I diabetes.

The placebo-controlled, Australian trial will evaluate safety as the primary endpoint. Secondary endpoints include biomarker analyses, insulin production, glycemia and antibody production. The company expects to complete enrollment by year end and to report data in 3Q18...